BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ikeda S, Sugihara T, Hoshino Y, Matsuki Y, Nagahara T, Okano JI, Kitao S, Fujioka Y, Yamamoto K, Isomoto H. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Med 2020;63:188-97. [PMID: 32884438 DOI: 10.33160/yam.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ikeda S, Sugihara T, Kihara T, Matsuki Y, Nagahara T, Takata T, Kitao S, Okura T, Yamamoto K, Isomoto H. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. Diagnostics (Basel) 2021;11:2316. [PMID: 34943553 DOI: 10.3390/diagnostics11122316] [Reference Citation Analysis]
2 Hatanaka T, Kakizaki S, Saito N, Nakano Y, Nakano S, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y, Kashiwabara K, Yoshinaga T, Tojima H, Naganuma A, Uraoka T. Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. Intern Med 2021;60:2167-74. [PMID: 33612679 DOI: 10.2169/internalmedicine.6574-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Reference Citation Analysis]
4 Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clin Exp Hepatol 2021;7:172-7. [PMID: 34295984 DOI: 10.5114/ceh.2021.106864] [Reference Citation Analysis]
5 Hatanaka T, Kosone T, Saito N, Takakusagi S, Tojima H, Naganuma A, Takagi H, Uraoka T, Kakizaki S. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. JGH Open 2021;5:1183-9. [PMID: 34622006 DOI: 10.1002/jgh3.12650] [Reference Citation Analysis]